Lerner Neil

Chief Accounting Officer Neil Lerner buys 15,000 shares at $1.89, his second open-market purchase in 36 months, as stock trades sharply below 52-week highs.

Neil Lerner, Chief Accounting Officer of Compass Therapeutics, purchased 15,000 shares on the open market at $1.89, marking his second open-market purchase within the past 36 months. The stock is currently trading well below its 52-week high, having fallen sharply over the recent period and approaching its 52-week low. His prior open-market purchase at this company, made roughly a year ago, was followed by significant gains over the subsequent quarter, demonstrating well-timed entry into the stock. This repeat buying at substantially lower prices mirrors the pattern of his previous purchase—entering when the stock is under pressure. The company is not currently profitable and carries substantial operating losses, making this a purchase into fundamentals weakness rather than strength. Lerner's return to the open market after his prior successful buy suggests he views current price levels as an opportunity, though the deteriorated financial position since his last purchase makes this a contrarian move into an earlier-stage therapeutic biotech in distress.

CAO Lerner Neil buys 20,000 CMPX shares at $1.42; stock down -40.9% in 30 days, company unprofitable.

Neil Lerner, Chief Accounting Officer of Compass Therapeutics, purchased 20,000 shares at $1.42 on 2025-04-07, increasing his holdings to 320,000 shares. The purchase occurs amid significant recent price weakness: the stock has declined 40.9% over the past 30 days and trades at $1.59, down 59.2% from its 52-week high of $3.90. The company reported zero revenue in its latest quarter and net income of $-10,481,000 over its most recent full fiscal year, indicating ongoing operational losses. An insider buy by a finance officer during a period of steep declines and operational challenges warrants scrutiny into whether this represents conviction in a recovery path or reflects a lower entry point for long-term vesting/retention dynamics typical of C-suite equity positions.